The short version of PPARδ agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-27. Anything still debated is marked as such rather than presented as settled.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
=== Failed proposed changes === 2015: Proposals to amalgamate local councils in Wellington and Northland were accepted by the Local Government Commission for consideration, although following consultation they ultimately were not formed into a final proposal. The status quo remains. 2015: Amalgamation of four local councils and the regional council in Hawke's Bay was proposed by the Local Government Commission. A district wide referendum was held in Sep-2015, and the proposal was defeated by 66% of voters. 2015: The Local Government Commission received a proposal to review local government arrangements on the West Coast. In August 2016 the Commission decided to progress the application. The Commission then invited alternative applications to the original application. The Commission's call for alternative reorganisation applications or other proposals for change to West Coast local government arrangements closed on 15 March 2017. The Commission received 23 responses, 19 of which made specific proposals for change. In December 2017 the Local Government Commission determined its preferred option for local government reorganisation on the West Coast to be the transfer of district plan preparation from the Buller, Grey and Westland district councils to the West Coast Regional Council. 2017: The Local Government Commission received a proposal to amalgamate the Masterton, Carterton and South Wairarapa District Councils into a combined Wairarapa District Council. The proposal was defeated by referendum with 59% of voters rejecting the proposed merger.
== Synthetic ligands == The non-peptide NPS receptor antagonist SHA-68 blocks the effects of NPS in animals and is anxiogenic. Several peptide derived NPS agonists and antagonists have also been developed.
Perhaps the most serious oral condition caused by smoking (including pipe smoking) is oral cancer. However, smoking also increases the risk for various other oral diseases, some almost completely exclusive to tobacco users. Roughly half of periodontitis or inflammation around the teeth cases are attributed to current or former smoking. Smokeless tobacco causes gingival recession and white mucosal lesions. Up to 90% of periodontitis patients who are not helped by common modes of treatment are smokers. Smokers have significantly greater loss of bone height than non-smokers, and the trend can be extended to pipe smokers to have more bone loss than non-smokers. Smoking traditional cigarettes, e-cigarettes, and heat-not-burn products also affects the salivary cytokine levels needed in immune responses. Traditional cigarettes slightly intensify the immune response in long-term smokers compared to non-smokers, with long-term smokers showing higher levels of IFN-γ than non-smokers. E-cigarettes and heat-not-burn products, while marketed as a healthier alternative, have been shown to inhibit immune response function. Users of these products show lower levels of salivary cytokines, chemokines, and growth factors that function to keep the immune response strong and active in the mouth. Smoking has been proven to be an important factor in teeth staining. Halitosis or bad breath is common among tobacco smokers. Tooth loss is 2 to 3 times higher in smokers than in non-smokers.
=== 31 March === The International Monetary Fund approved a $15.6 billion support package for Ukraine to assist with the country's economic recovery. The package would be the first of its kind for a country at war. The World Bank estimated that around US$411 billion was needed for Ukraine's recovery and for rebuilding from the invasion.
Sources: en.wikipedia.org
The International Supply Chain Education Alliance (ISCEA) is a certifying body. Founded in 2003 and currently holding over 100,000 members, ISCEA has its World HQ office in Beachwood, OH, USA and regional offices in LATAM, EMEA and APAC. ISCEA is the governing body for the Ptak Prize. Besides Certified Supply Chain Manager (CSCM) certification, ISCEA has developed several professional certification programs that include: Certified Supply Chain Analyst (CSCA), Certified Lean Master (CLM), Certified RFID Supply Chain Manager (RFIDSCM), Certified Demand Driven Planner (CDDP), Certified HealthCare Supply Chain Analyst (CHSCA); and Certified Lean Six Sigma Yellow Belt (CLSSYB), Green Belt (CLSSGB) and Black Belt (CLSSBB).
Within maritime environments one of the largest pest threats to waterlogged wood includes shipworms (Teredinidae). Shipworms bore into wood that is immersed in seawater. Within a museum exhibit or storage environment and post treatment of waterlogged wood objects, there are a number of wood-boring pests that feast on wood. Two of which include the wood-boring/powderpost beetle and termites. Wood-boring beetles can include several different types within the board category. Each type of beetle could target a different type of wood. Evidence of pest deterioration includes powder-like frass near entry and exit holes within the wood. Termites also feast on and live below the surface of the wood so they can be more difficult to detect. Termites discharge six-sided fecal pellets and, if found on a wooden object, could be used to determine the type of pest damage
=== Sexual dysfunction === Sexual dysfunction in people with diabetes is often a result of physical factors such as nerve damage and poor circulation, and psychological factors such as stress and/or depression caused by the demands of the disease. The most common sexual issues in males with diabetes are problems with erections and ejaculation: "With diabetes, blood vessels supplying the penis's erectile tissue can get hard and narrow, preventing the adequate blood supply needed for a firm erection. The nerve damage caused by poor blood glucose control can also cause ejaculate to go into the bladder instead of through the penis during ejaculation, called retrograde ejaculation. When this happens, semen leaves the body in the urine." Another cause of erectile dysfunction is reactive oxygen species created as a result of the disease. Antioxidants can be used to help combat this. Sexual problems are common in women who have diabetes, including reduced sensation in the genitals, dryness, difficulty/inability to orgasm, pain during sex, and decreased libido. Diabetes sometimes decreases estrogen levels in females, which can affect vaginal lubrication. Less is known about the correlation between diabetes and sexual dysfunction in females than in males. Oral contraceptive pills can cause blood sugar imbalances in women who have diabetes. Dosage changes can help address that, at the risk of side effects and complications. Women with type 1 diabetes show a higher than normal rate of polycystic ovarian syndrome (PCOS).
== Animal sexual behavior == GnRH activity influences a variety of sexual behaviors. Increased levels of GnRH facilitate sexual displays and behavior in females. GnRH injections enhance copulation solicitation (a type of courtship display) in white-crowned sparrows. In mammals, GnRH injections facilitate sexual behavior of female display behaviors as shown with the musk shrew's (Suncus murinus) reduced latency in displaying rump presents and tail wagging towards males. An elevation of GnRH raises males' testosterone capacity beyond a male's natural testosterone level. Injections of GnRH in male birds immediately after an aggressive territorial encounter results in higher testosterone levels than is observed naturally during an aggressive territorial encounter. A compromised GnRH system has adverse effects on reproductive physiology and maternal behavior. In comparison to female mice with a normal GnRH system, female mice with a 30% decrease in GnRH neurons are poor caregivers to their offspring. These mice are more likely to leave their pups scattered rather than grouped together, and will take significantly longer to retrieve their pups.
=== Molecular docking simulations === The development and application of bench-top chemoproteomics assays is often time consuming and cost-prohibitive. Molecular docking simulations have emerged as relatively low-cost, high-throughput means for ranking the strength of small molecule-protein interactions. Molecular docking requires accurate modeling of both ligand and protein conformation at atomic resolution, and is therefore aided by empirical determination of protein structure, often through orthogonal methods such as x-ray crystallography and cryogenic electron microscopy. Molecular docking strategies are categorized by the type of information that is already known about the ligand and protein of interest.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.